EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B	docetaxel + BPI 2358 Sensitive: B - Late Trials docetaxel + BPI 2358 Sensitive : B
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr Sensitive : C2	tislelizumab-jsgr Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2	MK-2870 Sensitive: C2 – Inclusion Criteria MK-2870 Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials erlotinib + cabozantinib tablet Sensitive : C3	erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials erlotinib + cabozantinib tablet Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3
EGFR wild-type	Lung Adenocarcinoma	EGFR wild-type	Lung Adenocarcinoma	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	iparomlimab/tuvonralimab Sensitive: C3 – Early Trials iparomlimab / tuvonralimab Sensitive : C3	iparomlimab/tuvonralimab Sensitive: C3 – Early Trials iparomlimab / tuvonralimab Sensitive : C3
EGFR wild-type	Lung Non-Small Cell Squamous Cancer	EGFR wild-type	Lung Non-Small Cell Squamous Cancer	iparomlimab/tuvonralimab Sensitive: C3 – Early Trials iparomlimab / tuvonralimab Sensitive : C3	iparomlimab/tuvonralimab Sensitive: C3 – Early Trials iparomlimab / tuvonralimab Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	ABBV-647 Sensitive: C3 – Early Trials ABBV-647 Sensitive : C3	ABBV-647 Sensitive: C3 – Early Trials ABBV-647 Sensitive : C3
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3

EGFR wild-type

Associations